TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study

Key Points

• Poor prognosis is associated with TP53 mutation in diffuse large B-cell lymphoma, highlighting a critical biomarker.
• In patients with this lymphoma, those with TP53 mutations show significantly shorter overall survival rates compared to others.
• Observational analysis at a single center revealed genetic alterations in the TP53 gene affecting patient outcomes.
• Findings underscore the need for targeted therapies that address the impact of TP53 mutations on treatment plans.